Expansion of a proliferative, exhausted CD8 + T cell population over the course of treatment
PD
Among all patients, the increase in CD8 + proliferating T cells was greatest in the patient with CR (1.7-fold change vs. mean 0.8 in PD/SD/PR), which led us to further investigate this T cell subset. From pre-treatment to C2D1, CD8 + proliferating T cells increased from 5.2 to 9.2% in the patient with CR but reduced from 3.3 to 1.1% in the patient with PD (Fig. We next assessed dynamics of PD-1Phenotype changes of PD-1 high proliferating T cells over the course of treatment with doxorubicin and pembrolizumab for one patient with CR. CD127 expression and CD38 expression was compared between Ki-67- (gray), PD-1Since the generation of a PD-1